Erlibulin Study - Metastatic Breast Cancer Study
Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Breast Cancer We have conducted this study with in one and half month recruitment time line and we have made 100% of recruitment from our end. This was the post marketing surveillance study and the treatment for metastatic breast cancer patients. All the recruited subjects have completed their total cycle of therapy. In the middle of the November 2018 we have got the EC approval and we have completed our
target with in just one and half months. The total number of chemotherapy cycle was 6 and all the patients have completed the cycles. Now they are in stable condition according to PI and the Clinical assessment reports. This was a DCGI submitted study. Our site was IPGME&R, SSKM Hospital Kolkata and PI (Prof) Dr. Aloke Ghosh Dastidar (Oncologist).
This study was conducted, run and managed by CliniMed LifeSciences Pvt.Ltd.